Show simple item record

dc.contributor.authorOry, Fernando de
dc.contributor.authorEchevarría, José Manuel
dc.contributor.authorKafatos, George
dc.contributor.authorAnastassopoulou, Cleo
dc.contributor.authorAndrews, Nick
dc.contributor.authorBackhouse, Josephine
dc.contributor.authorBerbers, Guy A M
dc.contributor.authorBruckova, Blazena
dc.contributor.authorCohen, Daniel I
dc.contributor.authorMelker, Hester E de
dc.contributor.authorDavidkin, Irja
dc.contributor.authorGabutti, Giovanni
dc.contributor.authorHesketh, Louise M
dc.contributor.authorJohansen, Kari
dc.contributor.authorJokinen, Sari
dc.contributor.authorJones, Lindsay
dc.contributor.authorLinde, Anika
dc.contributor.authorMiller, Elisabeth
dc.contributor.authorMossong, Joël
dc.contributor.authorNardone, Anthony
dc.contributor.authorRota, Maria Cristina
dc.contributor.authorSauerbrei, Andreas
dc.contributor.authorSchneider, François
dc.contributor.authorSmetana, Zahava
dc.contributor.authorTischer, Annedore
dc.contributor.authorTsakris, Athanassios
dc.contributor.authorVranckx, Robert
dc.date.accessioned2006-10-26T10:48:40Z
dc.date.available2006-10-26T10:48:40Z
dc.date.issued2006-06-01
dc.identifier.citationJ. Clin. Virol. 2006, 36(2):111-8en
dc.identifier.issn1386-6532
dc.identifier.pmid16616612
dc.identifier.doi10.1016/j.jcv.2006.01.017
dc.identifier.urihttp://hdl.handle.net/10029/5603
dc.description.abstractBACKGROUND: The aim of the European Sero-Epidemiology Network (ESEN2) is to harmonise the serological surveillance of vaccine-preventable diseases in Europe. OBJECTIVE: To allow comparison of antibody prevalence in different countries by standardising results into common units. STUDY DESIGN: For varicella zoster virus (VZV), a reference laboratory established a panel of 148 samples, characterised by indirect enzyme-immunoassay (ELISA), indirect immunofluorescence, and complement fixation test. Fifty-seven samples were also studied by the fluorescence antibody to membrane antigen test. The geometric mean of the antibody activity (GMAA) obtained from four ELISA determinations was used to characterise each sample of the panel as positive (GMAA: >100 mIU/ml), equivocal (GMAA: 50-100 mIU/ml) or negative (GMAA: <50 mIU/ml) for antibody to VZV (anti-VZV). Thirteen laboratories, using five different ELISA tests, tested the panel. RESULTS: Agreement with the reference laboratory was above 85% in all cases, and the R(2) values obtained from regression analysis of the quantitative results were always higher than 0.87. Finally, the regression equations could be used to convert national values into a common unitage. CONCLUSION: This study confirmed that results for anti-VZV obtained by different ELISA methods can be converted into common units, enabling the comparison of the seroprevalence profiles obtained in the participant countries.
dc.format.extent315572 bytes
dc.format.mimetypeapplication/pdf
dc.language.isoenen
dc.titleEuropean seroepidemiology network 2: Standardisation of assays for seroepidemiology of varicella zoster virus.en
dc.typeArticleen
dc.format.digYES
refterms.dateFOA2018-12-18T13:48:03Z
html.description.abstractBACKGROUND: The aim of the European Sero-Epidemiology Network (ESEN2) is to harmonise the serological surveillance of vaccine-preventable diseases in Europe. OBJECTIVE: To allow comparison of antibody prevalence in different countries by standardising results into common units. STUDY DESIGN: For varicella zoster virus (VZV), a reference laboratory established a panel of 148 samples, characterised by indirect enzyme-immunoassay (ELISA), indirect immunofluorescence, and complement fixation test. Fifty-seven samples were also studied by the fluorescence antibody to membrane antigen test. The geometric mean of the antibody activity (GMAA) obtained from four ELISA determinations was used to characterise each sample of the panel as positive (GMAA: >100 mIU/ml), equivocal (GMAA: 50-100 mIU/ml) or negative (GMAA: <50 mIU/ml) for antibody to VZV (anti-VZV). Thirteen laboratories, using five different ELISA tests, tested the panel. RESULTS: Agreement with the reference laboratory was above 85% in all cases, and the R(2) values obtained from regression analysis of the quantitative results were always higher than 0.87. Finally, the regression equations could be used to convert national values into a common unitage. CONCLUSION: This study confirmed that results for anti-VZV obtained by different ELISA methods can be converted into common units, enabling the comparison of the seroprevalence profiles obtained in the participant countries.


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
ory.pdf
Size:
306.7Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record